Table 2.
Comparison between EGFR mutation (19Del) status analysis by DHPLC, ME-Liquidchip, and Scorpion-ARMS in peripheral blood and Scorpion-ARMS in tumor tissue
| No | Scorpion-ARMS in T | Total | |
|---|---|---|---|
|
|
|||
| (+) | (−) | ||
| DHPLC in B | |||
| (+) | 0 | 1 | 1 |
| (−) | 7 | 26 | 33 |
| Total | 7 | 27 | 34 |
| Scorpion-ARMS in B | |||
| (+) | 3 | 4 | 7 |
| (−) | 4 | 23 | 27 |
| Total | 7 | 27 | 34 |
| ME-Liquidchip in B | |||
| (+) | 2 | 5 | 7 |
| (−) | 5 | 22 | 27 |
| Total | 7 | 27 | 34 |
Abbreviations: EGFR, epidermal growth factor receptor; 19Del, exon 19 mutation of EGFR; DHPLC, denaturing high-performance liquid chromatography; ME-Liquidchip, mutant-enriched liquidchip; Scorpion-ARMS, Scorpion Amplification Refractory Mutation System; T, tumor tissue; B, peripheral blood.